Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly

4Q Revenues: $5.2 billion (+22%)

4Q Earnings: $854.4 million (earnings were $132 million 4Q2006)*

FY Revenues: $18.6 billion (+19%)

FY Earnings: $3.0 billion (+11%)

Comments: Sales of Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve collectively grew 55% to $1.7 billion, and accounted for 33% of total 4Q sales, compared with 26% in 4Q06. Zyprexa sales for the quarter were up 10% to $1.3 billion and up 9% FY to $4.8 billion. 4Q Cymbalta sales were $628.3 million (+48%) and $2.1 billion for the year (+60%). Gemzar sales in the quarter were $425 million (+15%) and were $1.6 billion for the year (+13%). 4Q and FY R&D expenses were up 11% to $953.6 million and $3.5 billion, respectively.  

*4Q2006 earnings were impacted by asset impairment, restructuring and Zyprexa product liability charges.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters